Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term study of 0.5% STN1011402 ophthalmic cream in allergic conjunctivitis
jRCT2031210639Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of epinastine in allergic conjunctivitis (AC) (2 arms), sponsored by Santen Pharmaceutical. Primary endpoints: Safety and Subjective ocular symptom score. Started Mar 2022; status: completed.
02
Drugs
epinastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2031210639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210639.